2021 Fiscal Year Final Research Report
Significance of autoantibodies in patients treated with immune checkpoint inhibitors
| Project/Area Number |
19K08617
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | University of Occupational and Environmental Health, Japan |
|---|
Principal Investigator |
Minoru Satoh 産業医科大学, 産業保健学部, 教授 (90162487)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
矢寺 和博 産業医科大学, 医学部, 教授 (40341515)
田中 晋 産業医科大学, 産業保健学部, 講師 (70280253)
丈達 陽順 産業医科大学, 医学部, 助教 (90793175)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 自己抗体 / 自己免疫 / 免疫チェックポイント阻害薬 / 肺がん / 抗核抗体 / 免疫療法 |
|---|
| Outline of Final Research Achievements |
Immune checkpoint inhibitors (ICI) is an anti-neoplastic drug with a new mechanism and has been used extensively. Adverse events via autoimmune mechanism have been reported, however, there is no establisshed biomarkers to predict them. In the present study, various autoantibodies were tested prior to the administration of ICI in patients with lung cancer and their association with the development of thyroid disease and interstitial lung disease (ILD) were analyzed. Positive anti-thyroid autoantibodies prior to the ICI was associated with the development of hypothyroidism. Among the autoantibodies seen in connective tissue diseases, anti-Ro52 autoantibodies, which has been reported to be associated with the presence of ILD, severe and treatment resistance, and poor prognosis of ILD, was associated with the development of ILD after ICI therapy. These results suggest that testing autoantibodies before ICI treatment can be biomarkers to predict immune related adverse events.
|
| Free Research Field |
自己免疫
|
| Academic Significance and Societal Importance of the Research Achievements |
新たな機序による抗癌剤の免疫チェックポイント阻害薬(ICI)は、自己免疫学的機序を介した有害事象が問題であるが、その発症を予測する因子は不明である。本研究ではICIによる重篤な有害事象である間質性肺炎と治療前の抗Ro52抗体陽性との関連が示唆された。抗Ro52抗体が、臨床的に有用なバイオマーカーとなるのに加え、間質性肺炎の病態解明、将来の新規治療の開発にも結びつく可能性がある。ICIは高価な薬であるが、全例に有効ではなく有害事象も少なくないので、適切に用いることが重要である。ICIによる有害事象、効果を予測するバイオマーカーの発見は、患者予後の改善、医療費の抑制にもつながると考えられる。
|
